This article is more than 5 years old. Information may no longer be current.

Bevacizumab effective in venous occlusion secondary to macular edema

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

GUADALAJARA, Mexico — Bevacizumab improves vision and decreases macular thickness in cases of venous occlusion secondary to macular edema, according to a study presented here.

Lidia Griselda Álvarez Rivera, MD, and colleagues analyzed the effects of a 0.1 mL dose of Avastin (bevacizumab, Genentech) at 1 and 3 months follow-up in a prospective, experimental case series. The study involved 11 eyes with branch retinal vein occlusion and four eyes with central retinal vein occlusion.

The researchers presented the results in a poster at the Mexican Congress of Ophthalmology. They found that mean visual acuity had improved from 20/400 at baseline to 20/100 at 1-month follow-up and to 20/60 by 3 months. Macular thickness also decreased, from 334.60 µm at baseline to 223.4 µm at 3 months follow-up, according to the study.

No adverse events were reported, the authors noted.